Optiver Holding
CTKB icon

Optiver Holding’s Cytek Biosciences CTKB Stock Holding History

Optiver Holding’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-3,175
Closed -$13.9K – 2831
2026
Q1 		$13.9K Buy
+3,175
New +$15K ﹤0.01% 1164
2025
Q4 		– Sell
-1,036
Closed -$3.6K – 2588
2025
Q3 		$3.6K Buy
+1,036
New +$3.89K ﹤0.01% 2050

Other funds holding CTKB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $386M AUM 2.37% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Optiver Holding's CTKB Position: Q2 2026 in Review

Optiver Holding sold out of Cytek Biosciences (CTKB) in Q2 2026, closing a stake of 3,175 shares — an estimated $13.9K sold.

Optiver Holding first reported a position in CTKB in Q3 2025 and held it in 2 quarters. The position peaked at $13.9K in Q1 2026. 154 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

  • Optiver Holding reported no remaining Cytek Biosciences position as of Q2 2026 after selling out during the quarter.
  • Optiver Holding sold 3,175 Cytek Biosciences shares in Q2 2026, an estimated $13.9K.
  • Optiver Holding first reported a position in Cytek Biosciences in Q3 2025 and held it in 2 quarters.
  • Optiver Holding's Cytek Biosciences position peaked at $13.9K in Q1 2026.
  • 154 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on Optiver Holding's 13F filing for Q2 2026, filed 12 Aug 2026.